Significant Increase in Residual DNA Damage as a Possible Mechanism of Radiosensitization by Gemcitabine

[1]  R. Class,et al.  [Combined radiotherapy and gemcitabine. Evaluation of clinical data based on experimental knowledge]. , 2002, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[2]  G. Peters,et al.  End-joining deficiency and radiosensitization induced by gemcitabine. , 2001, Cancer research.

[3]  H. Frommhold,et al.  Strahlentherapeutische Strategien in der multimodalen Therapie des resektablen und nicht resektablen Pankreaskarzinoms , 2000, Strahlentherapie und Onkologie.

[4]  U. Baum,et al.  Adjuvant and Neoadjuvant Radiochemotherapy in Ductal Pancreatic Carcinoma , 2000, Strahlentherapie und Onkologie.

[5]  E. Brammer.  Relationship between cellular radiosensitivity and non-repaired double-strand breaks studied for different growth states, dose rates and plating conditions in a normal human fibroblast line , 2000, International journal of radiation biology.

[6]  J. Dahm-Daphi,et al.  Comparison of biological effects of DNA damage induced by ionizing radiation and hydrogen peroxide in CHO cells. , 2000, International journal of radiation biology.

[7]  C. Rübe,et al.  [Radiotherapeutic strategies in the multimodal therapy of resectable and nonresectable pancreatic carcinoma]. , 2000, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[8]  C. Mcginn,et al.  Radiosensitization by gemcitabine. , 1999, Oncology.

[9]  H. Böttcher,et al.  [The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine]. , 1999, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[10]  V. Grégoire,et al.  The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. , 1999, International journal of radiation biology.

[11]  K. Ang,et al.  Enhancement of tumor radioresponse in vivo by gemcitabine. , 1999, Cancer research.

[12]  M Wannenmacher,et al.  Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. , 1998, International journal of radiation oncology, biology, physics.

[13]  V. Grégoire,et al.  Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. , 1998, International journal of radiation biology.

[14]  T. Lawrence,et al.  Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  M. Millward,et al.  Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. , 1997, Radiation oncology investigations.

[16]  H. Pinedo,et al.  Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine. , 1996, Biochemical pharmacology.

[17]  T. Lawrence,et al.  Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. , 1996, International journal of radiation oncology, biology, physics.

[18]  C. Mcginn,et al.  Radiosensitizing nucleosides. , 1996, Journal of the National Cancer Institute.

[19]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[20]  G. Peters,et al.  Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.

[21]  Benjamin Rs.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .

[22]  T. Lawrence,et al.  Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. , 1994, Cancer research.

[23]  W. E. Schy,et al.  Effect of a template-located 2',2'-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3'-->5'exonuclease-) fragment. , 1993, Cancer research.

[24]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[25]  Y Z Xu,et al.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.

[26]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[27]  J. Bollinger,et al.  2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. , 1991, Journal of medicinal chemistry.

[28]  P. Olive,et al.  Comparison between pulsed-field and constant-field gel electrophoresis for measurement of DNA double-strand breaks in irradiated Chinese hamster ovary cells. , 1991, International journal of radiation biology.

[29]  W. Plunkett,et al.  Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. , 1990, Cancer research.

[30]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.

[31]  T. Kinsella,et al.  The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers. , 1984, International journal of radiation oncology, biology, physics.